Guggenheim Capital’s Fulgent Genetics FLGT Stock Holding History

Guggenheim Capital’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-9,897	Closed	-$309K	–	1894
2023 Q1	$309K	Buy	+9,897	New	+$319K	﹤0.01%	1674
2022 Q3	–	Sell	-8,970	Closed	-$489K	–	1954
2022 Q2	$489K	Buy	8,970 +4,243	+90%	+$233K	﹤0.01%	1592
2022 Q1	$295K	Buy	4,727 +51	+1%	+$3.36K	﹤0.01%	1892
2021 Q4	$470K	Sell	4,676 -1,945	-29%	-$171K	﹤0.01%	1709
2021 Q3	$596K	Sell	6,621 -5,707	-46%	-$519K	﹤0.01%	1677
2021 Q2	$1.14M	Sell	12,328 -714	-5%	-$57K	0.01%	1420
2021 Q1	$1.26M	Sell	13,042 -12,238	-48%	-$1.26M	0.01%	1277
2020 Q4	$1.32M	Buy	+25,280	New	+$1.06M	0.01%	1183

Other funds holding FLGT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DSCM

Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Guggenheim Capital's FLGT Position: Q2 2023 in Review

Guggenheim Capital sold out of Fulgent Genetics (FLGT) in Q2 2023, closing a stake of 9,897 shares — an estimated $309K sold.

Guggenheim Capital first reported a position in FLGT in Q4 2020 and held it in 8 quarters. The position peaked at $1.32M in Q4 2020. 214 funds tracked by Wall St. Rank hold FLGT as of Q2 2023.

Guggenheim Capital reported no remaining Fulgent Genetics position as of Q2 2023 after selling out during the quarter.
Guggenheim Capital sold 9,897 Fulgent Genetics shares in Q2 2023, an estimated $309K.
Guggenheim Capital first reported a position in Fulgent Genetics in Q4 2020 and held it in 8 quarters.
Guggenheim Capital's Fulgent Genetics position peaked at $1.32M in Q4 2020.
214 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2023.

Based on Guggenheim Capital's 13F filing for Q2 2023, filed 11 Aug 2023.